Darzalex (daratumumab) / Genmab, J&J  >>  Phase 1
Welcome,         Profile    Billing    Logout  

35 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Darzalex (daratumumab) / J&J
NCT02918331: A Study of JNJ-54767414 (Daratumumab) in Combination With Lenalidomide and Dexamethasone in Japanese Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-dose Therapy and Autologous Stem Cell Transplantation

Completed
1b
7
Japan
Daratumumab (16 mg/kg), Lenalidomide, Dexamethasone
Janssen Pharmaceutical K.K.
Multiple Myeloma
10/17
03/20
NCT02497378: A Study of JNJ-54767414 (Daratumumab) in Combination With Bortezomib and Dexamethasone (D-Vd) in Japanese Participants With Relapsed or Refractory Multiple Myeloma

Completed
1b
8
Japan
JNJ-54767414 (Daratumumab), Bortezomib, VELCADE, Dexamethasone
Janssen Pharmaceutical K.K.
Multiple Myeloma
03/18
03/18
NCT02116569: A Study of Daratumumab in Japanese Participants With Relapsed or Refractory Multiple Myeloma

Completed
1
9
Japan
Daratumumab, JNJ-54767414
Janssen Pharmaceutical K.K.
Multiple Myeloma
09/15
09/15
CyBorD-Dara, NCT02955810: Cyclophosphamide-Bortezomib-Dexamethasone (CyBorD) With Daratumumab (DARA)

Unknown status
1
18
Europe
Daratumumab, Darzalex, Cyclophosphamide, Cytoxan, Bortezomib, Velcade, Dexamethasone
National University of Ireland, Galway, Ireland, Janssen Pharmaceuticals, Cancer Trials Ireland
Multiple Myeloma
09/18
11/20
EQUULEUS, NCT01998971: A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma

Checkmark Subgroup analysis of MMY1001 at ASCO 2018 [screenshot]
Jun 2018 - Jun 2018: Subgroup analysis of MMY1001 at ASCO 2018 [screenshot]
Checkmark In combination with KRd for NDMM at ASH 2017 [screenshot]
Dec 2017 - Dec 2017: In combination with KRd for NDMM at ASH 2017 [screenshot]
Checkmark In combination with Kd for relapsed MM at ASH 2017 [screenshot]
More
Completed
1
240
Europe, US
Daratumumab, Velcade, Pomalidomide, Dexamethasone, Melphalan, Prednisone, Thalidomide, Diphenhydramine, Acetaminophen, Carfilzomib, Lenalidomide, Montelukast
Janssen Research & Development, LLC
Multiple Myeloma
01/19
01/24
NCT03068351: Study of Bromodomain and Extra-Terminal Protein (BET) Inhibitor RO6870810 as Mono- and Combination Therapy in Advanced Multiple Myeloma

Completed
1
24
Europe, US, RoW
RO6870810, daratumumab
Hoffmann-La Roche
Multiple Myeloma
08/19
08/19
NCT03591744: Daratumumab, Bortezomib, Dexamethasone, Pegylated Liposomal Doxorubicin Hydrochloride, and Lenalidomide in Treating Participants With Plasma Cell Leukemia

Withdrawn
1
0
US
Bortezomib, [(1R)-3-Methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]boronic Acid, LDP 341, MLN341, PS-341, PS341, Velcade, Daratumumab, Anti-CD38 Monoclonal Antibody, Darzalex, HuMax-CD38, JNJ-54767414, Dexamethasone, Aacidexam, Adexone, Aknichthol Dexa, Alba-Dex, Alin, Alin Depot, Alin Oftalmico, Amplidermis, Anemul mono, Auricularum, Auxiloson, Baycuten, Baycuten N, Cortidexason, Cortisumman, Decacort, Decadrol, Decadron, Decalix, Decameth, Decasone R.p., Dectancyl, Dekacort, Deltafluorene, Deronil, Desamethasone, Desameton, Dexa-Mamallet, Dexa-Rhinosan, Dexa-Scheroson, Dexa-sine, Dexacortal, Dexacortin, Dexafarma, Dexafluorene, Dexalocal, Dexamecortin, Dexameth, Dexamethasonum, Dexamonozon, Dexapos, Dexinoral, Dexone, Dinormon, Fluorodelta, Fortecortin, Gammacorten, Hexadecadrol, Hexadrol, Lokalison-F, Loverine, Methylfluorprednisolone, Millicorten, Mymethasone, Orgadrone, Spersadex, Visumetazone, Lenalidomide, CC-5013, CC5013, CDC 501, Revlimid, Pegylated Liposomal Doxorubicin Hydrochloride, ATI-0918, Caelyx, DOX-SL, Doxil, Doxilen, Doxorubicin HCl Liposome, doxorubicin hydrochloride liposome, Duomeisu, Evacet, LipoDox, Liposomal Adriamycin, liposomal doxorubicin hydrochloride, Liposomal-Encapsulated Doxorubicin, Pegylated Doxorubicin HCl Liposome, S-Liposomal Doxorubicin, Stealth Liposomal Doxorubicin, TLC D-99
City of Hope Medical Center, National Cancer Institute (NCI)
Plasma Cell Leukemia
10/19
10/19
NCT02852837: Dose Escalation Study of JNJ-54767414 (Daratumumab) in Chinese Participants With Relapsed or Refractory Multiple Myeloma Who Failed at Least 2 Prior Lines of Systemic Therapy

Completed
1
50
RoW
Daratumumab, JNJ-54767414
Janssen Research & Development, LLC
Multiple Myeloma
12/19
12/19
NCT03311828: Copper 64Cu-DOTA-Daratumumab Positron Emission Tomography in Diagnosing Patients With Relapsed Multiple Myeloma

Completed
1
12
US
Daratumumab, 945721-28-8, Anti-CD38 Monoclonal Antibody, Darzalex, HuMax-CD38, JNJ-54767414, Imaging Agent, Image Enhancement Agent, Positron Emission Tomography, Medical Imaging, PET, PET Scan, positron emission tomography scan, proton magnetic resonance spectroscopic imaging, Pharmacological Study
City of Hope Medical Center
Recurrent Plasma Cell Myeloma, Plasma Cell Myeloma, Secondary Amyloidosis
01/20
06/23
NCT02431208: A Study of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) Alone or in Combination With an Immunomodulatory Drug and/or Daratumumab in Participants With Multiple Myeloma (MM)

Completed
1
85
US
Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody, Tecentriq, MPDL3280A, "ATZ", Daratumumab, Darzalex, "DAR", Lenalidomide, Revlimid, "LEN", Pomalidomide, Pomalyst, "POM", Dexamethasone
Hoffmann-La Roche
Multiple Myeloma
03/21
03/21
NCT04121260: A Study of Subcutaneous Delivery of JNJ-54767414 in Chinese Participants With Multiple Myeloma

Completed
1
21
RoW
Daratumumab, JNJ-54767414
Janssen Research & Development, LLC
Multiple Myeloma
04/21
10/23
NCT04280328: Study of Ciforadenant in Combination With Daratumumab in Patients With Relapsed or Refractory Multiple Myeloma

Completed
1
7
US
Ciforadenant, CPI-444, daratumumab
Corvus Pharmaceuticals, Inc.
Multiple Myeloma
09/21
03/22
CPD-DARA, NCT04667663: in Patients With Relapsed/Refractory Multiple Myeloma.

Active, not recruiting
1
20
Europe
Daratumumab, Darzalez, Cyclophosphamide, Pomalidomide, Pomalyst, Imnovid, Dexamethasone
Cancer Trials Ireland, Janssen Pharmaceuticals, Bristol-Myers Squibb
Multiple Myeloma
04/22
04/26
NCT04088903: Study of Daratumumab for Decreasing Circulating Antibodies in Sensitized Patients Awaiting Heart Transplantation

Withdrawn
1
0
NA
Daratumumab
Ronald Witteles
Allosensitization, Heart Transplant Failure and Rejection
04/23
04/23
OMNIA-2, NCT05641324: A Study of ANV419 Alone or in Combination With Approved Treatments in Patients With Multiple Myeloma

Terminated
1
4
Europe
ANV419, Lenalidomide with low-dose dexamethasone, Daratumumab
Anaveon AG
Multiple Myeloma, Relapsed Cancer, Refractory Multiple Myeloma, Adult Disease, Hematologic Diseases
07/23
07/23
NCT04614636: FT538 in Subjects With Advanced Hematologic Malignancies

Terminated
1
42
US
FT538, Cyclophosphamide, Fludarabine, Daratumumab, Darzalex, Elotuzumab, Empliciti
Fate Therapeutics
Acute Myeloid Leukemia, AML, Adult, Multiple Myeloma, Myeloma
07/23
08/23
NCT05974969: A Study to Assess the PK, PD, Safety and Immunogenicity of Single IV Infusion of BCD-264 and Darzalex in Healthy Subjects

Completed
1
146
RoW
BCD-264, Darzalex
Biocad
Healthy
08/23
08/23
NCT03177460: Daratumumab or FMS Inhibitor JNJ-40346527 Before Surgery in Treating Patients With High-Risk, Resectable Localized or Locally Advanced Prostate Cancer

Completed
1
33
US
Daratumumab, Anti-CD38 Monoclonal Antibody, Darzalex, HuMax-CD38, JNJ-54767414, FMS Inhibitor JNJ-40346527, JNJ-40346527, Radical Prostatectomy, Prostatovesiculectomy
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Prostate Adenocarcinoma, Stage III Prostate Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8, Stage IIIB Prostate Cancer AJCC v8, Stage IIIC Prostate Cancer AJCC v8, Testosterone Greater Than 150 ng/dL
01/24
01/24
NCI-2018-00159, NCT03447808: Daratumumab and Ibrutinib in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia

Active, not recruiting
1
15
US
Daratumumab, Anti-CD38 Monoclonal Antibody, Darzalex, HuMax-CD38, JNJ-54767414, Ibrutinib, BTK Inhibitor PCI-32765, CRA-032765, Imbruvica, PCI-32765, Laboratory Biomarker Analysis, Pharmacological Study
Jennifer Woyach
Chronic Lymphocytic Leukemia
12/24
12/24
NCT05562882: A Clinical Trial to Assess Safety and Efficacy of Daratumumab in the Treatment of Primary Immune Thrombocytopenia

Not yet recruiting
1
20
NA
Daratumumab Injection, Darzalex
Institute of Hematology & Blood Diseases Hospital
Immune Thrombocytopenia
12/23
05/24
HLX15-001, NCT05679258: A Study to Compare the PK , Safety, Tolerability, and Immunogenicity of HLX15 With Daratumumab in Male Subjects

Completed
1
172
RoW
HLX15, Recombinant anti-CD38 fully humanized monoclonal antibody injection, US-sourced DARZALEX®, Daratumumab Injection, CN-sourced DARZALEX®, EU-sourced DARZALEX®
Shanghai Henlius Biotech
Multiple Myeloma
03/24
06/24
MajesTEC-2, NCT04722146: A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma

Checkmark MajesTEC-2 study of Tecvayli combo Darzalex Faspro and lenalidomide
Dec 2022 - Dec 2022: MajesTEC-2 study of Tecvayli combo Darzalex Faspro and lenalidomide
Active, not recruiting
1
140
Europe, US, RoW
Teclistamab, JNJ-64007957, Daratumumab, Pomalidomide, Lenalidomide, Bortezomib, Nirogacestat
Janssen Research & Development, LLC
Multiple Myeloma
10/24
02/25
NCT03473730: Daratumumab in Treating Patients With Muscle Invasive Bladder Cancer or Metastatic Kidney Cancer

Active, not recruiting
1
17
US
Biopsy, Bx, Daratumumab, Anti-CD38 Monoclonal Antibody, Darzalex, HuMax-CD38, JNJ-54767414, Laboratory Biomarker Analysis, Metastasectomy, Nephrectomy
M.D. Anderson Cancer Center, Janssen Research & Development, LLC, National Cancer Institute (NCI)
Bladder Urothelial Carcinoma, Clear Cell Renal Cell Carcinoma, Malignant Urinary System Neoplasm, Metastatic Kidney Carcinoma, Stage IV Renal Cell Cancer AJCC v8
06/24
06/24
CAMMA 1, NCT04910568: A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma

Recruiting
1
184
Europe, Canada, Japan, US, RoW
Cevostamab, Tocilizumab, Actemra/RoActemra, Pomalidomide, Daratumumab, Dexamethasone
Genentech, Inc., Hoffmann-La Roche
Multiple Myeloma
09/24
07/25
NCT06287944: 225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome

Not yet recruiting
1
15
US
Actinium Ac 225-DOTA-Daratumumab, 225Ac-DOTA-Daratumumab, [225Ac]-DOTA-Daratumumab, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Biopsy of Bone Marrow, Biopsy, Bone Marrow, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, CT, CT Scan, tomography, Daratumumab, Daratumumab Biosimilar HLX15, Daratumumab-fihj, Darzalex, HLX15, HuMax-CD38, JNJ-54767414, Echocardiography, EC, Fludarabine, Fluradosa, Hematopoietic Cell Transplantation, HCT, Hematopoietic Stem Cell Infusion, Hematopoietic Stem Cell Transplantation, HSCT, SCT, Stem Cell Transplant, stem cell transplantation, Stem Cell Transplantation, NOS, Indium In 111-DOTA-Daratumumab, 111In-DOTA-Daratumumab, [111In]-DOTA-Daratumumab, Melphalan, Alanine Nitrogen Mustard, CB-3025, L-PAM, L-Phenylalanine Mustard, L-Sarcolysin, L-Sarcolysin Phenylalanine mustard, L-Sarcolysine, Melphalanum, Phenylalanine Mustard, Phenylalanine Nitrogen Mustard, Sarcoclorin, Sarkolysin, WR-19813, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide Ventriculography, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Radionuclide Imaging, NM, Nuclear Medicine, nuclear medicine scan, radioimaging, Radionuclide Scanning, Scan, Scintigraphy, Single Photon Emission Computed Tomography, Medical Imaging, Single Photon Emission Computed Tomography, Single Photon Emission Tomography, Single-Photon Emission Computed, single-photon emission computed tomography, SPECT, SPECT imaging, SPECT SCAN, SPET, ST, tomography, emission computed, single photon, Tomography, Emission-Computed, Single-Photon, Sirolimus, AY 22989, RAPA, Rapamune, Rapamycin, SILA 9268A, WY-090217, Tacrolimus, FK 506, FK-506, Fujimycin, Hecoria, Prograf, Protopic, Tacforius, Total Marrow and Lymphoid Irradiation, TMLI
City of Hope Medical Center, National Cancer Institute (NCI)
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndrome
02/27
02/27
NCT03432741: Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer

Suspended
1
39
US
Belinostat, Beleodaq, PXD 101, PXD101, Carfilzomib, Kyprolis, PR-171, Copanlisib Hydrochloride, 5-Pyrimidinecarboxamide, 2-Amino-N-(2,3-dihydro-7-methoxy-8-(3-(4-morpholinyl)propoxy)imidazo(1,2-C)quinazolin-5-yl)-, Hydrochloride (1:2), Aliqopa, BAY 80-6946 Dihydrochloride, BAY-80-6946 Dihydrochloride, Copanlisib Dihydrochloride, Daratumumab, Anti-CD38 Monoclonal Antibody, Darzalex, HuMax-CD38, JNJ-54767414, Fludeoxyglucose F-18, 18FDG, FDG, Fludeoxyglucose (18F), fludeoxyglucose F 18, Fludeoxyglucose F18, Fluorine-18 2-Fluoro-2-deoxy-D-Glucose, Fluorodeoxyglucose F18, Gemcitabine Hydrochloride, dFdCyd, Difluorodeoxycytidine Hydrochloride, FF 10832, FF-10832, FF10832, Gemcitabine HCI, Gemzar, LY-188011, LY188011, Laboratory Biomarker Analysis, Nivolumab, BMS-936558, CMAB819, MDX-1106, NIVO, Nivolumab Biosimilar CMAB819, ONO-4538, Opdivo, Obinutuzumab, Anti-CD20 Monoclonal Antibody R7159, GA-101, GA101, Gazyva, huMAB(CD20), R7159, RO 5072759, RO-5072759, RO5072759, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, Rituximab, ABP 798, BI 695500, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT-P10, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, MabThera, Monoclonal Antibody IDEC-C2B8, PF-05280586, Rituxan, Rituximab ABBS, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar IBI301, Rituximab Biosimilar JHL1101, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, Rituximab Biosimilar SIBP-02, rituximab biosimilar TQB2303, rituximab-abbs, RTXM83, Truxima, Romidepsin, Antibiotic FR 901228, Depsipeptide, FK228, FR901228, Istodax, N-[(3S,4E)-3-Hydroxy-7-mercapto-1-oxo-4-heptenyl]-D-valyl-D-cysteinyl-(2Z)-2-amino-2-butenoyl-L-valine, (4->1) Lactone, Cyclic, Saline, ISOTONIC SODIUM CHLORIDE SOLUTION, Sodium Chloride 0.9%, Trastuzumab, ABP 980, ALT02, Anti-c-ERB-2, Anti-c-erbB2 Monoclonal Antibody, Anti-ERB-2, Anti-erbB-2, Anti-erbB2 Monoclonal Antibody, Anti-HER2/c-erbB2 Monoclonal Antibody, Anti-p185-HER2, c-erb-2 Monoclonal Antibody, HER2 Monoclonal Antibody, Herceptin, Herceptin Biosimilar PF-05280014, Herceptin Trastuzumab Biosimilar PF-05280014, Herzuma, Kanjinti, MoAb HER2, Monoclonal Antibody c-erb-2, Monoclonal Antibody HER2, Ogivri, Ontruzant, PF-05280014, rhuMAb HER2, RO0452317, SB3, Trastuzumab Biosimilar ABP 980, Trastuzumab Biosimilar ALT02, trastuzumab biosimilar EG12014, Trastuzumab Biosimilar HLX02, Trastuzumab Biosimilar PF-05280014, Trastuzumab Biosimilar SB3, Trastuzumab Biosimilar SIBP-01, Trastuzumab-anns, Trastuzumab-dkst, Trastuzumab-dttb, Trastuzumab-pkrb, Trastuzumab-qyyp, Trazimera
Mayo Clinic, National Cancer Institute (NCI)
Breast Adenocarcinoma, Metastatic Breast Carcinoma, Recurrent Breast Carcinoma, Recurrent Hodgkin Lymphoma, Recurrent Mycosis Fungoides, Recurrent Non-Hodgkin Lymphoma, Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Refractory Breast Carcinoma, Refractory Hodgkin Lymphoma, Refractory Mycosis Fungoides, Refractory Nodal Marginal Zone Lymphoma, Refractory Non-Hodgkin Lymphoma, Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Stage IV Breast Cancer AJCC v6 and v7
04/25
05/26
NCI-2022-03039, NCT05363111: Radioimmunotherapy (111Indium/225Actinium-DOTA-daratumumab) for the Treatment of Relapsed/Refractory Multiple Myeloma

Recruiting
1
15
US
Actinium Ac 225-DOTA-Daratumumab, 225Ac-DOTA-Daratumumab; [225Ac]-DOTA-Daratumumab, Daratumumab, Anti-CD38 Monoclonal Antibody, Darzalex, HuMax-CD38, JNJ-54767414, Indium In 111-DOTA-Daratumumab, 111In-DOTA-Daratumumab; [111In]-DOTA-Daratumumab
City of Hope Medical Center, National Cancer Institute (NCI)
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
03/25
03/25
NCT03283917: Daratumumab, Ixazomib, and Dexamethasone in AL Amyloidosis

Active, not recruiting
1
21
US
Daratumumab, Anti-CD38 Monoclonal Antibody, Darzalex, HuMax-CD38, JNJ-54767414, Dexamethasone, Aacidexam, Adexone, Aknichthol Dexa, Alba-Dex, Alin, Alin Depot, Alin Oftalmico, Amplidermis, Anemul mono, Auricularum, Auxiloson, Baycuten, Baycuten N, Cortidexason, Cortisumman, Decacort, Decadrol, Decadron, Decalix, Decameth, Decasone R.p., Dectancyl, Dekacort, Deltafluorene, Deronil, Desamethasone, Desameton, Dexa-Mamallet, Dexa-Rhinosan, Dexa-Scheroson, Dexa-sine, Dexacortal, Dexacortin, Dexafarma, Dexafluorene, Dexalocal, Dexamecortin, Dexameth, Dexamethasonum, Dexamonozon, Dexapos, Dexinoral, Dexone, Dinormon, Fluorodelta, Fortecortin, Gammacorten, Hexadecadrol, Hexadrol, Lokalison-F, Loverine, Methylfluorprednisolone, Millicorten, Mymethasone, Orgadrone, Spersadex, Visumetazone, Ixazomib, MLN-2238, MLN2238
M.D. Anderson Cancer Center, Janssen Pharmaceuticals, Takeda
Newly Diagnosed Primary Amyloidosis, Recurrent Primary Amyloidosis, Refractory Primary Amyloidosis
05/25
05/25
iinnovate-2, NCT05556616: A Study of Modakafusp Alfa in Adult Participants With Multiple Myeloma

Completed
1
15
Europe, US, RoW
Modakafusp alfa, TAK-573, Lenalidomide, Bortezomib, Carfilzomib, Daratumumab, Pomalidomide
Takeda
Multiple Myeloma
01/24
06/24
AMC-105, NCT04139304: A Study of Daratumumab and Dose-Adjusted EPOCH in Plasmablastic Lymphoma

Active, not recruiting
1
15
US
Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Daratumumab, Anti-CD38 Monoclonal Antibody, Darzalex, HuMax-CD38, JNJ-54767414, Doxorubicin, Adriablastin, Hydroxydaunomycin, Hydroxyl Daunorubicin, Hydroxyldaunorubicin, Doxorubicin Hydrochloride, 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI), ADM, Adriacin, Adriamycin, Adriamycin Hydrochloride, Adriamycin PFS, Adriamycin RDF, ADRIAMYCIN, HYDROCHLORIDE, Adriamycine, Adriblastina, Adriblastine, Adrimedac, Chloridrato de Doxorrubicina, DOX, DOXO-CELL, Doxolem, Doxorubicin HCl, Doxorubicin.HCl, Doxorubin, Farmiblastina, FI 106, FI-106, hydroxydaunorubicin, Rubex, Etoposide, Demethyl Epipodophyllotoxin Ethylidine Glucoside, EPEG, Lastet, Toposar, Vepesid, VP 16, VP 16-213, VP-16, VP-16-213, VP16, Prednisone, .delta.1-Cortisone, 1, 2-Dehydrocortisone, Adasone, Cortancyl, Dacortin, DeCortin, Decortisyl, Decorton, Delta 1-Cortisone, Delta-Dome, Deltacortene, Deltacortisone, Deltadehydrocortisone, Deltasone, Deltison, Deltra, Econosone, Lisacort, Meprosona-F, Metacortandracin, Meticorten, Ofisolona, Orasone, Panafcort, Panasol-S, Paracort, Perrigo Prednisone, PRED, Predicor, Predicorten, Prednicen-M, Prednicort, Prednidib, Prednilonga, Predniment, Prednisone Intensol, Prednisonum, Prednitone, Promifen, Rayos, Servisone, SK-Prednisone, Vincristine, LEUROCRISTINE, VCR, Vincrystine, Vincristine Sulfate, Kyocristine, Leurocristine sulfate, Leurocristine, sulfate, Oncovin, Vincasar, Vincosid, Vincrex, Vincristine, sulfate
AIDS Malignancy Consortium, National Cancer Institute (NCI), Janssen Scientific Affairs, LLC, Montefiore Medical Center, Memorial Sloan Kettering Cancer Center, AIDS and Cancer Specimen Resource, The Emmes Company, LLC
Plasmablastic Lymphoma, Ann Arbor Stage I Diffuse Large B-Cell Lymphoma, Ann Arbor Stage II Diffuse Large B-Cell Lymphoma, Ann Arbor Stage III Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma
07/25
08/27
DARALAM, NCT05749276: Escalation of Doses of Daratumumab in Combination With Chemotherapy (Idarubicin and Cytarabine) in Patients of 60 Years Old or More With Adverse Risk Acute Myeloblastic Leukemia (AML)

Not yet recruiting
1
12
NA
Darzalex
Nantes University Hospital
Adult Patients With Adverse Risk Acute Myeloblastic Leukemia
01/28
01/28
NCT05832216: Efficacy of Daratumumab to Overcome Platelet Transfusion Refractoriness in Patients With Aplastic Anemia

Recruiting
1
10
RoW
Daratumumab
Institute of Hematology & Blood Diseases Hospital
Aplastic Anemia, Platelet Transfusion Refractoriness
03/26
12/26
NCT05308654: A Study to Assess the Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma Receiving Oral ABBV-453 Tablets

Recruiting
1
360
Europe, US, RoW
ABBV-453, Dexamethasone, Daratumumab, Lenalidomide
AbbVie
Relapsed/Refractory Multiple Myeloma
08/26
08/26
ALLO-T-DART, NCT04972942: Targeted Immunotherapy After Myeloablative TBI-Based Conditioning & AlloHCT in CAYA With High Risk T-Cell ALL & Lymphoma

Recruiting
1
30
US
Daratumumab, Darzalex®
New York Medical College
T-cell Acute Lymphoblastic Leukemia, T-Cell Acute Lymphoblastic Lymphoma
09/27
09/28
NCT05259839: A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-383 in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma

Recruiting
1
270
Europe, Japan, US, RoW
ABBV-383, Dexamethasone, Lenalidomide, Pomalidomide, Nirogacestat, Daratumumab
TeneoOne Inc.
Relapsed/Refractory Multiple Myeloma
11/28
07/31

Download Options